Medy-Tox Inc (086900) - Net Assets

Latest as of September 2025: ₩467.65 Billion KRW ≈ $316.92 Million USD

Based on the latest financial reports, Medy-Tox Inc (086900) has net assets worth ₩467.65 Billion KRW (≈ $316.92 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩586.91 Billion ≈ $397.74 Million USD) and total liabilities (₩119.26 Billion ≈ $80.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Medy-Tox Inc (086900) strategic asset index to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric	Value
Current Net Assets	₩467.65 Billion
% of Total Assets	79.68%
Annual Growth Rate	20.47%
5-Year Change	95.02%
10-Year Change	314.85%
Growth Volatility	20.52

Medy-Tox Inc - Net Assets Trend (2013–2024)

This chart illustrates how Medy-Tox Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 086900 stock market capitalisation.

Annual Net Assets for Medy-Tox Inc (2013–2024)

The table below shows the annual net assets of Medy-Tox Inc from 2013 to 2024. Also explore 086900 year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Year	Net Assets	Change
2024-12-31	₩470.78 Billion ≈ $319.04 Million	-0.78%
2023-12-31	₩474.48 Billion ≈ $321.55 Million	+10.85%
2022-12-31	₩428.04 Billion ≈ $290.08 Million	+7.15%
2021-12-31	₩399.48 Billion ≈ $270.72 Million	+65.49%
2020-12-31	₩241.40 Billion ≈ $163.59 Million	-6.85%
2019-12-31	₩259.15 Billion ≈ $175.62 Million	+2.60%
2018-12-31	₩252.59 Billion ≈ $171.17 Million	+31.79%
2017-12-31	₩191.65 Billion ≈ $129.88 Million	+29.78%
2016-12-31	₩147.68 Billion ≈ $100.08 Million	+30.13%
2015-12-31	₩113.48 Billion ≈ $76.91 Million	+39.09%
2014-12-31	₩81.59 Billion ≈ $55.29 Million	+34.45%
2013-12-31	₩60.68 Billion ≈ $41.13 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Medy-Tox Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 42521059200000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	₩425.21 Billion	91.15%
Common Stock	₩3.65 Billion	0.78%
Other Components	₩37.62 Billion	8.06%
Total Equity	₩466.48 Billion	100.00%

Medy-Tox Inc Competitors by Market Cap

The table below lists competitors of Medy-Tox Inc ranked by their market capitalization.

Company	Market Cap
Qingdao Hi-Tech Moulds & Plastics Technology Co. Ltd. SHE:301022	$306.29 Million
Interarch Building Products Limited NSE:INTERARCH	$306.32 Million
Companhia Brasileira de Distribuição SA:PCAR3	$306.37 Million
Wuhan Citms Technology Co Ltd SHG:688038	$306.52 Million
XiAn Global Printing Co Ltd SHE:002799	$306.28 Million
Fujian Yuanxiang New Materials Co. Ltd. A SHE:301300	$306.09 Million
Rana Gruber AS OL:RANA	$305.95 Million
AIM Industrial Growth Freehold and Leasehold Real Estate Investment Trust BK:AIMIRT	$305.91 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Medy-Tox Inc's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 469,462,692,180 to 466,475,912,000, a change of -2,986,780,180 (-0.6%).
Net income of 16,954,995,000 contributed positively to equity growth.
Dividend payments of 8,424,486,000 reduced retained earnings.
Share repurchases of 10,006,878,000 reduced equity.
New share issuances of 141,200,000 increased equity.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	₩16.95 Billion	+3.63%
Dividends Paid	₩8.42 Billion	-1.81%
Share Repurchases	₩10.01 Billion	-2.15%
Share Issuances	₩141.20 Million	+0.03%
Other Changes	₩-1.65 Billion	-0.35%
Total Change	₩-	-0.64%

Book Value vs Market Value Analysis

This analysis compares Medy-Tox Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.98x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
The price-to-book ratio has decreased from 3.04x to 0.98x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	₩22598.45	₩68700.00	x
2017-12-31	₩31047.07	₩68700.00	x
2018-12-31	₩40859.62	₩68700.00	x
2019-12-31	₩42167.01	₩68700.00	x
2020-12-31	₩39531.64	₩68700.00	x
2021-12-31	₩65971.37	₩68700.00	x
2022-12-31	₩67544.36	₩68700.00	x
2023-12-31	₩69765.75	₩68700.00	x
2024-12-31	₩70047.44	₩68700.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Medy-Tox Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 3.63%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 7.42%
• Asset Turnover: 0.37x
• Equity Multiplier: 1.32x
Recent ROE (3.63%) is below the historical average (21.21%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	23.57%	36.54%	0.49x	1.31x	₩8.24 Billion
2014	53.47%	57.49%	0.45x	2.07x	₩35.47 Billion
2015	37.27%	47.79%	0.43x	1.79x	₩30.94 Billion
2016	40.11%	44.45%	0.41x	2.19x	₩44.46 Billion
2017	36.58%	38.68%	0.48x	1.99x	₩50.94 Billion
2018	27.70%	34.05%	0.52x	1.56x	₩44.70 Billion
2019	10.11%	12.73%	0.49x	1.63x	₩290.81 Million
2020	-12.25%	-21.00%	0.30x	1.94x	₩-53.72 Billion
2021	23.57%	50.93%	0.32x	1.45x	₩54.21 Billion
2022	8.65%	18.97%	0.33x	1.39x	₩-5.79 Billion
2023	2.08%	4.41%	0.36x	1.30x	₩-37.19 Billion
2024	3.63%	7.42%	0.37x	1.32x	₩-29.69 Billion

Industry Comparison

This section compares Medy-Tox Inc's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $301,287,260,329
Average return on equity (ROE) among peers: -18.01%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Medy-Tox Inc (086900)	₩467.65 Billion	23.57%	0.26x	$306.29 Million
ORIENTBIO Inc. (002630)	$79.92 Billion	-17.35%	1.38x	$73.37 Million
Green Cross (005250)	$221.73 Billion	2.76%	8.07x	$293.85 Million
Green Cross Holdings Preference Shares (005257)	$1.88 Trillion	-2.88%	0.99x	$2.92 Million
Pharmicell (005690)	$55.99 Billion	-70.00%	0.14x	$441.61 Million
GeneOne Life Science Inc (011000)	$39.44 Billion	3.58%	0.21x	$32.81 Million
HLB Co. Ltd (028300)	$582.25 Billion	-32.21%	0.29x	$2.92 Billion
Mgenplus Co. Ltd. (032790)	$10.14 Billion	-54.19%	2.17x	$20.92 Million
Daesung Microbiological Labs. Co. Ltd (036480)	$36.31 Billion	4.18%	0.71x	$15.73 Million
Seoulin Bioscience Co.Ltd (038070)	$83.06 Billion	-0.14%	0.37x	$24.29 Million
Hyundai Bioscience Co. Ltd (048410)	$22.49 Billion	-13.82%	0.46x	$419.86 Million

About Medy-Tox Inc

KQ:086900 Korea Biotechnology

Market Cap

$306.29 Million

₩451.96 Billion KRW

Market Cap Rank

#14783 Global

#473 in Korea

Share Price

₩68700.00

Change (1 day)

-0.15%

52-Week Range

₩66900.00 - ₩138600.00

All Time High

₩671543.08